Department of Health and Human Services, through National Institutes of Health, awarded Exhalix, LLC of Corvallis, OR $350,000 under the SBIR program (Phase II), with work starting 2025-09-16 and running to 2027-09-15. It is one of 2 SBIR and STTR awards Exhalix, LLC received in the last two years, $715,249 in all. Each figure links to the federal record.
The award
| Recipient | Exhalix, LLC (Corvallis, OR) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $350,000 |
| Period of performance starts | 2025-09-16 |
| Period of performance ends | 2027-09-15 |
| Award number | R43TR005284 (grant, CFDA 93.350) |
| Assistance listing | 93.350, National Center for Advancing Translational Sciences |
| Signed | 2025-09-15 |
| Recipient registry id (UEI) | C1NVZ5M6E319 |
Want the whole picture on Exhalix, LLC?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Exhalix, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Exhalix, LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Genie:s: On-demand sulfide synthesis and delivery platform technology for ischemia therapy - project summary/abstract peripheral artery disease (pad) is a vascular insufficiency problem that affects more than 20 million
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-06-19 | Revision | 000 | $0 |
| 2025-09-15 | New | 000 | $350,000 |
Genie:s: On-demand sulfide synthesis and delivery platform technology for ischemia therapy - project summary/abstract peripheral artery disease (pad) is a vascular insufficiency problem that affects more than 20 million or nearly 7% of the u.s. Population. Nearly 1 in 10 pad patients eventually develop chronic limb threatening ischemia (clti) with a combined annual cost of $21B. Pad is caused by sustained endothelial dysfunction, which is a vascular disorder prevalent among smokers and diabetics, and IT is often missed until the symptoms become advanced enough to lead to clti. The resulting lower extremity ischemia in clti patients is associated with 25% limb loss and 25% mortality at the end of year 1. Hydrogen sulfide (H2S) is an endogenous gasotransmitter and signaling molecule synthesized by the endothelial layer. In addition to vasodilatory role, H2S is responsible for angiogenesis in endothelial cells through activation of pathways that include nitric oxide signaling and the canonical HIF-1 and vegf-a-mediated angiogenesis cascade. There is also significant evidence linking deficiency in endogenous H2S to endothelial dysfunction and consequently microvascular disorder and poor perfusion. Systemic administration of (exogenous) H2S donors has been shown to markedly improve the rate of regeneration in ischemic tissue. However, widespread clinical translation of systemic H2S ...
From the federal award record.
Other SBIR and STTR awards to Exhalix, LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-09-15 | Department of Health and Human Services | STTR Phase I | $365,249 | A hydrogen sulfide delivery technology for organ preservation therapy - project summary/ab (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Exhalix, LLCLook up Exhalix, LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.